TransCode Therapeutics (RNAZ) investor relations material

Executive summary

• Focused on immuno-oncology and targeted cancer therapies, advancing lead candidate TTX-MC138 and integrating Polynoma’s Seviprotimut-L vaccine after an October 2025 acquisition.

• Entered a licensing agreement with Unleash Immuno Oncolytics in March 2026, acquiring a preclinical adenovirus-based immunotherapy program.

• Ongoing Phase I/II clinical trial for TTX-MC138 showed safety and dose response; Phase IIa trial planned for 2026.

• Entered a Standby Equity Purchase Agreement (SEPA) with Yorkville in April 2026 for up to $14 million in equity and $6 million in convertible notes.

Financial highlights

• Net loss for Q1 2026 was $17.8 million, up from $12.1 million in Q1 2025, driven by $10.4 million in acquired in-process R&D expense for the Unleash license.

• Operating expenses rose to $17.8 million from $3.2 million year-over-year, reflecting increased R&D and G&A costs.

• Cash at March 31, 2026, was $12.8 million; accumulated deficit reached $115.6 million.

• No revenue generated; grant income declined to $140,000 from $348,000 year-over-year.

Outlook and guidance

• Cash and expected reimbursements are projected to fund operations through year-end 2026, but not for a full 12 months from the report date.

• Additional capital will be required to continue operations and advance clinical programs beyond 2026.

• Risks include inability to raise capital, potential Nasdaq delisting, and ongoing operating losses.